The marker study
- Conditions
- Hematological patients
- Registration Number
- NL-OMON27980
- Lead Sponsor
- Sanquin Southwest
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 40
Inclusion Criteria
1. Age > 18 years;
2. Hemato-oncological disease;
3. Sickle cell disease;
4. Informed consent
Exclusion Criteria
1. Active cardiovascular disease;
2. Recent thrombo-embolism.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy of platelet transfusion or red blood cell exchange transfusion in hemato-oncological patients and sickle cell patients, respectively, in relation to several endothelial activation markers.
- Secondary Outcome Measures
Name Time Method